ArticleCurrent microbiology2026
Macrophage-targeted Hyaluronic-acid Coated Liposomes Bearing Ursolic Acid for Visceral Leishmaniasis: In Vitro Characterisation and Pharmacokinetic Analysis.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ursolic acid (UA), a natural triterpene, demonstrated promising activity against visceral leishmaniasis (VL); however, its clinical use is limited by poor aqueous solubility (< 5.64 µg/mL), low permeability, hindered oral bioavailability (< 3%), and extensive first-pass metabolism. Hence, hyaluronic acid-coated ursolic acid-bearing liposomes (HA-UA-Lips) were formulated using the thin-film hydration method integrated with Box-Behnken Design (BBD). HA-UA-Lips displayed a vesicle size of 200.2 ± 5.2 nm, PDI of 0.164 ± 0.041, and zeta potential of -21.39 ± 0.27 mV. The surface topography analysis confirmed spherical shape and uniform dispersion of vesicles. Additionally, HA-UA-Lips indicated a significant (P < 0.0001) sustained release of drug after 72 h (70.4 ± 1.68%) as compared to ursolic acid-loaded liposomes (UA-Lips; 87.4 ± 2.61%). The IC
Indexed as
Identifiers
41706170What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.